Calithera Biosciences, Inc. (CALA - Free Report) was a big mover last session, as the company saw its shares rise over 17% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $10.85 to $14.30 in the past one-month time frame.
The company has seen one negative estimate revision in the last 30 days, while the Zacks Consensus Estimate moved higher suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if Friday’s jump can turn into more strength down the road.
Currently, Calithera Biosciences carries a Zacks Rank #3 (Hold).
A better-ranked stock in the same industry is MEI Pharma, Inc. (MEIP - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is CALA going up? Or down? Predict to see what others think: Up or Down
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time. One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Calithera Biosciences, Inc. (CALA - Free Report) was a big mover last session, as the company saw its shares rise over 17% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $10.85 to $14.30 in the past one-month time frame.
The company has seen one negative estimate revision in the last 30 days, while the Zacks Consensus Estimate moved higher suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if Friday’s jump can turn into more strength down the road.
Currently, Calithera Biosciences carries a Zacks Rank #3 (Hold).
A better-ranked stock in the same industry is MEI Pharma, Inc. (MEIP - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is CALA going up? Or down? Predict to see what others think: Up or Down
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time. One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MEIP - FREE
Get the latest research report on CALA - FREE